Last reviewed · How we verify
Conventional treatment
Conventional treatment is a Small molecule drug developed by Zhinan Yin, Ph.D.. It is currently FDA-approved. Also known as: metformin+sulfonylurea with dose escalation, Basiliximab and/or Infliximab, Antiviral drugs, Hepatoprotective drugs.
Conventional treatment refers to standard, established therapeutic approaches using approved drugs or procedures rather than novel or experimental interventions.
At a glance
| Generic name | Conventional treatment |
|---|---|
| Also known as | metformin+sulfonylurea with dose escalation, Basiliximab and/or Infliximab, Antiviral drugs, Hepatoprotective drugs, Plasma |
| Sponsor | Zhinan Yin, Ph.D. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Conventional treatment encompasses the use of well-established pharmacological agents, surgical procedures, and clinical protocols that have demonstrated safety and efficacy through extensive clinical experience and regulatory approval. These treatments form the standard of care for various diseases and conditions, serving as the baseline comparator in clinical trials and as first-line therapy in most clinical settings.
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer (NA)
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Targeted Therapy and Avelumab in Merkel Cell Carcinoma (PHASE1, PHASE2)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional treatment CI brief — competitive landscape report
- Conventional treatment updates RSS · CI watch RSS
- Zhinan Yin, Ph.D. portfolio CI
Frequently asked questions about Conventional treatment
What is Conventional treatment?
How does Conventional treatment work?
Who makes Conventional treatment?
Is Conventional treatment also known as anything else?
What development phase is Conventional treatment in?
Related
- Manufacturer: Zhinan Yin, Ph.D. — full pipeline
- Also known as: metformin+sulfonylurea with dose escalation, Basiliximab and/or Infliximab, Antiviral drugs, Hepatoprotective drugs, Plasma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing